Replies to post #461352 on NorthWest Biotherapeutics Inc (NWBO)

[MI Dendream]

I can’t dig up the poster itself, but I will never forget the images that I saw when I read the poster on the one Ovarian cancer patient who despite only injecting the primary tumor saw most all the metastatic tumors shrink away. The images of the necrotic tissue within the large primary tumor were quite impressive as well as the disappearing tumors. I think I may have the poster saved on my old Ipad if I can power it up.

If one recalls, it was the Direct data and presentations that propelled the stock to double digit stock price, not the DCVax-L trial.

https://www.prnewswire.com/news-releases/nw-bio-making-a-joint-poster-presentation-on-its-dcvax-direct-trial-at-the-29th-annual-sitc-meeting-281912681.html

If grapefruit juice could do that, there would be hundreds a Florida farmer billionaires right now.

It can’t

[biosectinvestor]

Survival data for DCVax Direct here, from last presentation:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168610997

But it was a safety trial, so with varying amounts by huge amounts of the vaccine and again only one tumor treated on patients effectively designated for hospice care and cut off from the standard of care for their various cancers.

More to come.

[jondoeuk]

I believe that because it was a safety trial, they only injected one tumor, but also saw systemic immune response, though the details I do not have and that is to the best of my recollection.

Others, such as REPL have injected just a single lesion, but the systemic immune response was able to impact distal and non-injected lesions, with a number of responses (from memory, the ORR was over 33% with RP2).